CO2018010024A2 - Complejos radiofarmacéuticos - Google Patents
Complejos radiofarmacéuticosInfo
- Publication number
- CO2018010024A2 CO2018010024A2 CONC2018/0010024A CO2018010024A CO2018010024A2 CO 2018010024 A2 CO2018010024 A2 CO 2018010024A2 CO 2018010024 A CO2018010024 A CO 2018010024A CO 2018010024 A2 CO2018010024 A2 CO 2018010024A2
- Authority
- CO
- Colombia
- Prior art keywords
- tissue
- directed
- chelator
- complex
- thorium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención proporciona un método para la formación de un complejo de torio dirigido a tejido, que comprende; a) formar un quelador octadentado que comprende cuatro restos de hidroxipiridinona (HOPO), sustituidos en la posición N con un grupo metilo y un resto de acoplamiento que termina en un grupo de ácido carboxílico; b) acoplar dicho quelador octadentado con al menos un resto dirigido a tejido que apunta a HER2; y c) poner en contacto dicho quelador dirigido a tejido con una solución acuosa que comprende un ion de al menos un isótopo de torio emisor alfa. También se proporcionan un método de tratamiento de una enfermedad neoplásica o hiperplásica que comprende la administración de tal complejo de torio dirigido a tejido, así como el complejo y las correspondientes formulaciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16162123 | 2016-03-24 | ||
PCT/EP2017/056503 WO2017162555A1 (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018010024A2 true CO2018010024A2 (es) | 2018-10-22 |
Family
ID=55745553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0010024A CO2018010024A2 (es) | 2016-03-24 | 2018-09-24 | Complejos radiofarmacéuticos |
Country Status (19)
Country | Link |
---|---|
US (2) | US11260136B2 (es) |
EP (1) | EP3432936A1 (es) |
JP (2) | JP2019513699A (es) |
CN (1) | CN108778347A (es) |
AR (1) | AR107957A1 (es) |
AU (1) | AU2017239018A1 (es) |
BR (1) | BR112018069485A2 (es) |
CA (1) | CA3018607A1 (es) |
CL (1) | CL2018002695A1 (es) |
CO (1) | CO2018010024A2 (es) |
IL (1) | IL261329B (es) |
JO (1) | JOP20170072B1 (es) |
MX (1) | MX2018011629A (es) |
PE (1) | PE20190168A1 (es) |
SG (2) | SG11201806548UA (es) |
TW (1) | TWI757273B (es) |
UA (1) | UA125749C2 (es) |
UY (1) | UY37167A (es) |
WO (1) | WO2017162555A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
WO2020169537A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
UA95902C2 (ru) * | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
US20090214420A1 (en) * | 2005-04-01 | 2009-08-27 | Medvet Science Pty. Ltd. | Method of Diagnosis and Treatment and Agents Useful for Same |
PT2511301T (pt) * | 2006-08-04 | 2018-03-08 | Medimmune Ltd | Anticorpos humanos para erbb2 |
EP2423201B1 (en) | 2006-08-15 | 2017-10-04 | The Regents of the University of California | Luminescent macrocyclic lanthanide complexes |
EP2488199A1 (en) * | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
-
2017
- 2017-03-20 EP EP17710976.6A patent/EP3432936A1/en active Pending
- 2017-03-20 JP JP2018547324A patent/JP2019513699A/ja active Pending
- 2017-03-20 AU AU2017239018A patent/AU2017239018A1/en active Pending
- 2017-03-20 PE PE2018001861A patent/PE20190168A1/es unknown
- 2017-03-20 UA UAA201810278A patent/UA125749C2/uk unknown
- 2017-03-20 WO PCT/EP2017/056503 patent/WO2017162555A1/en active Application Filing
- 2017-03-20 BR BR112018069485A patent/BR112018069485A2/pt unknown
- 2017-03-20 US US16/087,040 patent/US11260136B2/en active Active
- 2017-03-20 SG SG11201806548UA patent/SG11201806548UA/en unknown
- 2017-03-20 MX MX2018011629A patent/MX2018011629A/es unknown
- 2017-03-20 CA CA3018607A patent/CA3018607A1/en active Pending
- 2017-03-20 SG SG10202009424TA patent/SG10202009424TA/en unknown
- 2017-03-20 CN CN201780017966.8A patent/CN108778347A/zh active Pending
- 2017-03-21 TW TW106109303A patent/TWI757273B/zh active
- 2017-03-22 JO JOP/2017/0072A patent/JOP20170072B1/ar active
- 2017-03-23 UY UY0001037167A patent/UY37167A/es not_active Application Discontinuation
- 2017-03-23 AR ARP170100720A patent/AR107957A1/es unknown
-
2018
- 2018-08-22 IL IL261329A patent/IL261329B/en active IP Right Grant
- 2018-09-24 CL CL2018002695A patent/CL2018002695A1/es unknown
- 2018-09-24 CO CONC2018/0010024A patent/CO2018010024A2/es unknown
-
2022
- 2022-01-21 US US17/581,808 patent/US20220143229A1/en active Pending
- 2022-08-30 JP JP2022136797A patent/JP2022173214A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
UA125749C2 (uk) | 2022-06-01 |
EP3432936A1 (en) | 2019-01-30 |
IL261329A (en) | 2018-10-31 |
CA3018607A1 (en) | 2017-09-28 |
BR112018069485A2 (pt) | 2019-07-30 |
PE20190168A1 (es) | 2019-02-01 |
WO2017162555A1 (en) | 2017-09-28 |
IL261329B (en) | 2021-04-29 |
US11260136B2 (en) | 2022-03-01 |
TW201736389A (zh) | 2017-10-16 |
UY37167A (es) | 2017-10-31 |
AR107957A1 (es) | 2018-07-04 |
TWI757273B (zh) | 2022-03-11 |
US20190091354A1 (en) | 2019-03-28 |
SG11201806548UA (en) | 2018-08-30 |
SG10202009424TA (en) | 2020-11-27 |
CL2018002695A1 (es) | 2019-01-18 |
US20220143229A1 (en) | 2022-05-12 |
MX2018011629A (es) | 2019-03-14 |
JP2019513699A (ja) | 2019-05-30 |
AU2017239018A1 (en) | 2018-08-16 |
CN108778347A (zh) | 2018-11-09 |
JP2022173214A (ja) | 2022-11-18 |
JOP20170072B1 (ar) | 2022-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800136A (es) | Complejos radio-farmacéuticos | |
DOP2017000143A (es) | Complejos radiofarmacéuticos | |
CO2018010024A2 (es) | Complejos radiofarmacéuticos | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
EA201890282A1 (ru) | Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты | |
EA201990093A1 (ru) | Двухкомпонентная композиция | |
PH12017500859A1 (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof | |
BR112017014849A2 (pt) | Processo para preparação de ácido hialurônico- butirato e uso de um ácido hialurônico-butirato |